Gandrala, D., Mallavarapu, K. M. V. T., Ayyagari, S., Hariharan, N., Naidu, C. C. K., Kodandapani, S., Fonseca, D., Pinninti, R., Ladda, P. S., Sanath, K., Tewani, R. K., Pathi, N., Rajappa, S. J. (2026). Neoadjuvant intravenous biosimilar pertuzumab and trastuzumab versus subcutaneous pertuzumab/trastuzumab/hyaluronidase (Phesgo) in HER2-positive breast cancer: A real-world comparative study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e12604